Skip to main content
SpringerLink
Log in

New Anticoagulant Strategies

Current Status and Future Potential

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rosenberg RD. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, et al., editors. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia: JB Lippincott, 1993: 837–60

    Google Scholar 

  2. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565–74

    Article  PubMed  CAS  Google Scholar 

  3. Hirsh J, Levine MN. Low molecular weight heparins. Blood 1992; 79: 1–17

    PubMed  CAS  Google Scholar 

  4. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619–23

    Article  PubMed  CAS  Google Scholar 

  5. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990; 86: 385–91

    Article  PubMed  CAS  Google Scholar 

  6. Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemostas 1991; 66: 141–52

    CAS  Google Scholar 

  7. Rydel TJ, Ravichandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 1990; 249: 277–80

    Article  PubMed  CAS  Google Scholar 

  8. Maraganore JM, Chao B, Joseph ML, et al. Anticoagulant activity of synthetic hirudin fragments. J Biol Chem 1989; 264: 8692–8

    PubMed  CAS  Google Scholar 

  9. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095–101

    Article  PubMed  CAS  Google Scholar 

  10. Kline T, Hammond C, Bourdon P, et al. Hirulog peptides with scissile bond replacements resistant to thrombin cleavage. Biochem Biophys Res Comm 1991: 177; 1049–55

    Article  PubMed  CAS  Google Scholar 

  11. Weitz JI, Hirsh. Antithrombins: their potential as antithrombotic agents. Ann Rev Med 1992; 43: 9–16

    Article  PubMed  CAS  Google Scholar 

  12. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33–42

    Article  PubMed  CAS  Google Scholar 

  13. Vu TKH, Wheaton VI, Hung DT, et al. Domains specifying thrombin-receptor interaction. Nature 1991; 353: 674–7

    Article  PubMed  CAS  Google Scholar 

  14. Vu TKH, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057–68

    Article  PubMed  CAS  Google Scholar 

  15. Coller BS. A new murine monoclonal antibody reports on activation-dependent change in the conformation and/or micro-environment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101–8

    Article  PubMed  CAS  Google Scholar 

  16. Ruoslahti E, Peirschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491–7

    Article  PubMed  CAS  Google Scholar 

  17. Gould RJ, Polokoff MA, Freidman PA, et al. Integrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med 1990; 195: 168–71

    PubMed  CAS  Google Scholar 

  18. Yasuda T, Gold HK, Kohmura C, et al. Intravenous and endobronchial administrations of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking penta-peptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation. Arterioscler Thromb 1993; 13: 738–47

    Article  PubMed  CAS  Google Scholar 

  19. Bar-Shavit R, Elder A, Vlodavasky I. Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J Clin Invest 1989; 84: 1096–104

    Article  PubMed  CAS  Google Scholar 

  20. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855–8

    Article  PubMed  CAS  Google Scholar 

  21. Francis CW, Markham RE, Barlow GH, et al. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220

    PubMed  CAS  Google Scholar 

  22. Eisenberg PR, Miletich JP, Sobel BE. Factors responsible for the differential procoagulant effects of diverse plasminogen activators in plasma. Fibrinolysis 1991; 5: 217–24

    CAS  Google Scholar 

  23. Popma JJ, Topol EJ. Adjuncts to thrombolysis for myocardial reperfusion. Ann Intern Med 1991; 115: 34–44

    PubMed  CAS  Google Scholar 

  24. Klement P, Borm A, Hirsh J, et al. The effect of thrombin inhibitors on tissue plasminogen activator-mediated thrombolysis in a rat model. Thromb Haemostasis 1992; 68: 64–8

    CAS  Google Scholar 

  25. Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281–6

    Article  PubMed  CAS  Google Scholar 

  26. Yasuda T, Gold HD, Fallon JT, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988; 81: 1284–91

    Article  PubMed  CAS  Google Scholar 

  27. Hsia J, Kleiman NS, Aguirre F, et al. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. J Am Coll Cardiol 1992; 20: 31–5

    Article  PubMed  CAS  Google Scholar 

  28. deBono DP, Simoons ML, Tijssen J, et al. Early intravenous heparin improves coronary patency in thrombolysis with recombinant human tissue-type plasminogen activator. Br Heart J 1992; 67: 122–8

    Article  CAS  Google Scholar 

  29. Lidon RM, Theroux P, Bonan R, et al. Hirulog as adjunctive therapy to streptokinase in acute myocardial infarction [abstract]. J Am Coll Cardiol 1993; 21: 419

    Article  Google Scholar 

  30. Cannon CP, McCabe CH, Henry TD, et al. Hirudin reduces reocclusion compared to heparin following thrombolysis in acute myocardial infarction: results of the TIMI 5 trial [abstract]. J Am Coll Cardiol 1993; 21: 136

    Google Scholar 

  31. Kleinman NS, Ohman ME, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: results of the TAMI 8 pilot study. J Am Coll Cardiol 1993; 22: 318–9

    Article  Google Scholar 

  32. Heras M, Chesebro JH, Penny WJ, et al. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657–65

    Article  PubMed  CAS  Google Scholar 

  33. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622–9

    Article  PubMed  CAS  Google Scholar 

  34. Ellis SG, Tcheng JE, Navetta FL, et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis 1993; 4: 167–76

    Article  PubMed  CAS  Google Scholar 

  35. Tcheng JE, Kleinman NS, Miller MJ, et al. Chimeric antiplatelet GPIIb/IIIa receptor antibody (c-7E3) in elective PTCA: safety and platelet function inhibition [abstract]. Circulation 1992; 85: 590

    Google Scholar 

  36. EPIC Investigators. Use of a monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–61

    Article  Google Scholar 

  37. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina in angina pectoris: a multicenter, randomized, angiographic trial. Circulation 1994; 89: 1557–66

    Article  PubMed  CAS  Google Scholar 

  38. Lidon RM, Theroux P, Juneau M, et al. Initial experience with a direct antithrombin hirulog in unstable angina: anticoagulant, antithrombotic and clinical effects. Circulation 1993; 88: 1495–501

    Article  PubMed  CAS  Google Scholar 

  39. Gold HK, Gimple LW, Yasuda T, et al. Pharmacodynamic study of F(ab1)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina. J Clin Invest 1990; 86: 651–9

    Article  PubMed  CAS  Google Scholar 

  40. Agnelli G, Renga C, Weitz JI, et al. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood 1992; 80: 960–5

    PubMed  CAS  Google Scholar 

  41. Ginsberg JS, Hirsh J, Gent M, et al. A phase II study for hirulog in the prevention of venous thrombosis after major hip or knee surgery [abstract]. Circulation 1992; 86: 409

    Google Scholar 

  42. Eriksson BI, Kalebo P, Lindbratt S, et al. Is direct thrombin inhibition with hirudin a safe prophylaxis of thromboembolic complications after hip replacement [abstract]. Circulation 1992; 86: 410

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hamilton Civic Hospitals Research Center and McMaster University, 711 Concession Street, Hamilton, Ontario, L8V 1C3, Canada

    Jeffrey Weitz

Authors
  1. Jeffrey Weitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weitz, J. New Anticoagulant Strategies. Drugs 48, 485–497 (1994). https://doi.org/10.2165/00003495-199448040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199448040-00001

Keywords

Search

Navigation